Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in the United States.

The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug after several hundred fake units were seized outside the authorized supply chain.

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA seized the counterfeit products on April 9, 2025, and both Novo Nordisk and the FDA are testing the seized products' identify, safety and quality.